MedTrace Logo

Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer

NCT00636259 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2008-06-11

No results posted yet for this study

Summary

This study provides compassionate use of bicalutamide (Casodex) at a 150-mg dose for subjects with prostate cancer prior to it becoming commercially available. The patient will receive bicalutamide 150-mg as long as the physician feels that the subject is benefiting from this therapy and safety information is provided regularly to AstraZeneca. Treatment will be discontinued after bicalutamide 150-mg becomes commercially available.

Conditions

  • Adenocarcinoma of the Prostate

Interventions

DRUG

Bicalutamide (Casodex)

150mg

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00636259 on ClinicalTrials.gov